Robin Young, CEO

We are an early stage company creating, marketing and selling a platform of smart biologic implants. The technology we employ is unique because it is based on a particular set of protein, peptide and collagen technologies which not only mimic in certain ways adult stem cells but, importantly, are derived from existing U.S. Food and Drug Administration (“FDA”) approved biologics, known as allografts.  We are focusing on a certain type of immune privileged smart biologic allograft, known as human amniotic tissue.  These allografts are processed from human amniotic membranes and can be used for a wide range of medical applications, including burn treatment, wound care, nerve and tendon repair and many other types of medical procedures that require the covering, protection or repair of a patient’s integumental (native) tissue.